ScreenerHero

IOVAIovance Biotherapeutics, Inc.

NAS · US · Healthcare · Biotechnology · iovance.com
8.290USD+3.75%Mkt Cap: 3.76B $P/E: —

Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other so…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap3.76B $
Enterprise Value3.82B $
Revenue (TTM)324.97M $
Gross Profit90.32M $
Net Income (TTM)-390.98M $
Revenue/Share0.7920 USD
Last Price8.290 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees975
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-33.81
PEG—
EV/EBITDA-14.72
EV/Revenue11.76
P/S12.53
P/B5.53
EPS (TTM)-0.77
EPS (Forward)-0.27
52W Range
1.76087% of range9.300
52W High9.300 USD
52W Low1.760 USD
Profitability
Gross Margin34.28%
Oper. Margin-52.26%
EBITDA Margin-79.88%
Profit Margin-148.38%
ROE-55.97%
ROA-42.82%
Growth
Revenue Growth65.70%
Earnings Growth—
Cash Flow & Leverage
Operating CF-302.41M $
CapEx (TTM)33.84M $
FCF Margin-57.79%
FCF Yield-5.00%
Net Debt-251.67M $
Net Debt/EBITDA0.97
Balance Sheet
Debt/Equity0.07
Current Ratio4.34
Quick Ratio3.74
Book Value/Sh1.625 USD
Cash/Share0.6570 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:100
Split DateSep 26, 2013
Analyst Consensus
Rating1.7 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)9.333 USD
Upside (mean)+12.6%
Target Range4.000 USD – 14.00 USD
$4.000+12.6% to mean$14.00
# Analysts9
Ownership
Shares Out.452.97M
Float394.36M
Insiders0.34%
Institutions70.49%
Short Interest
Short Ratio6.1d
Short % Float23.60%
Short % Out.22.07%
Shares Short99.98M
Short (prev mo.)100.53M
Technical
SMA 504.954 (+67.4%)
SMA 2003.595 (+130.6%)
Beta0.70
S&P 52W Chg18.16%
Avg Vol (30d)18.87M
Avg Vol (10d)19.86M
Technical Indicators
RSI (14)80.8
MACD0.8402
MACD Signal0.5747
MACD Hist.+0.2654
BB Upper8.353 USD
BB Middle5.756 USD
BB Lower3.159 USD
BB Width90.24%
ATR (14)0.5895 USD
Vol Ratio (20d)1.55x